ClinicalTrials.gg
CompletedNCT01462786Updated May 6, 2016

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

A Phase 1 interventional study of ATX-101 in Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-06.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objectives of this trial are to evaluate the safety and tolerability of ATX-101 injections and to compare the pharmacokinetic profile of ATX-101 administered into subcutaneous fat in the submental area and abdomen.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of submental fat graded by the investigator as 3 or 4 using the SMF Rating Scale (Appendix C) as a guideline.
  2. Sufficient submental and abdominal fat such that the protocol-specified number of injections can be safely administered.
  3. Males or nonpregnant, nonlactating females who are aged 18 to 65 years, inclusive, on the date of dosing with ATX-101. Females must have a negative serum human chorionic gonadotropin (HCG) test result from a sample obtained during the screening period and after admission to the research facility for the first confinement period, but before the dose of study material. Females of status must not have had menses for at least one year and if younger than 55 years of age must have a serum FSH level ≥ 35 mIU/mL. Females of must agree to practice adequate , in the judgment of the investigator, during the course of the trial.
  4. A normal result on coagulation tests (PT, ) obtained within 28 days before subject's first dosing session.
  5. Serum test result of 12.0 g/dL or greater and negative , , and test result within 28 days before the dose of study material.
  6. Ability to comply with and understand the visit schedule and all of the protocol-specified tests and procedures.
  7. Medically able to undergo the administration of study material as determined by clinical and laboratory evaluations obtained within 28 days before dosing with study material for which the investigator identifies no abnormality.
  8. Signed obtained before any study-specific procedure is conducted.

Exclusion criteria

Exclusion Criteria:

  1. History of any intervention to treat submental or abdominal fat (e.g., liposuction, surgery, or lipolytic agents).
  2. History of trauma associated with the chin, neck, or abdominal areas, which in the judgment of the investigator may affect evaluation of safety or efficacy of treatment.
  3. Loose skin in the neck or chin area for which reduction in submental fat may, in the judgment of the investigator, result in a cosmetically unacceptable outcome.
  4. Prominent platysmal bands at rest that interfere with the evaluation of submental fat.
  5. Evidence of any cause of enlargement in the submental or abdominal area other than localized subcutaneous fat.
  6. Obesity as defined by a (BMI) > 34 at the screening visit. Refer to Appendix B.
  7. Any blood donation or significant blood loss within 56 days before the dose of study material or plasma donation within 7 days before the dose of study material.
  8. Any medical condition (e.g., respiratory, cardiovascular, hepatic, neurological disease, uncontrolled hypertension, thyroid dysfunction), that would interfere with the assessment of safety in this trial or would compromise the ability of the subject to undergo study procedures or to give .
  9. Treatment with fish oil, aspirin, or nonsteroidal anti-inflammatory agents (NSAIDS), except acetaminophen, within seven days before dosing, or any anticipated need for agents with anticoagulative effects (e.g., warfarin, heparin) during the course of the trial.
  10. Treatment with oral anticoagulants (e.g., warfarin) within 30 days before dosing with study material.
  11. Expected to require treatment with any systemic medication during the study period (excluding any protocol-specified treatments)
  12. Treatment with radio frequency, laser procedures, chemical peels, or dermal fillers in the neck or chin area within 12 months before the first treatment session, or botulinum toxin injections in the neck or chin area within 6 months before the first treatment session.
  13. History of sensitivity to any components of the study material or to topical anesthetics (e.g., lidocaine, benzocaine, novocaine).
  14. History of drug or alcohol abuse, in the judgment of the investigator, within two years before the dose of study material.
  15. Presence of a positive urine drug or alcohol screening test result obtained from a sample obtained during the screening period and/or after admission to the research facility for the confinement period, but before the dose of study material.
  16. Previous enrollment into a trial of ATX-101.
  17. Treatment with an agent within 30 days before dosing.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    ATX-101 in abdomen area

    Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session

    Drug: ATX-101

  • Experimental
    ATX-101 in submental area

    Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session

    Drug: ATX-101

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of ATX-101 injections as assessed by incidence, severity and duration of AEs of ATX-101 administered into subcutaneous fat in the submental and abdomen area

    This is a single center, open-label, crossover study in which subjects will receive 2 mg/cm2 ATX-101 as indicated below in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session. For the first dosing session dosing will occur on Day 0 with the 2nd dosing session occurring on Day 8. A final follow-up visit will occur on Day 14.

    Time frame: 2 weeks

Secondary outcomes

  1. To compare the pharmacokinetic profile (Cmax, tmax, AUC, half-life) of ATX-101 administered into subcutaneous fat in the submental and abdomen area

    Time frame: 2 weeks

07

Study locations

1 site
  • Cetero Research
    Fargo, North Dakota 58104, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2011
First posted
Oct 31, 2011
Start
Oct 2011
Primary completionActual
Nov 2011
CompletionActual
Dec 2011
Last update
May 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01462786
Responsible party
Sponsor
First posted
Oct 31, 2011
Start date
Oct 2011
Primary completion
Nov 2011
Completion
Dec 2011
Last update
May 6, 2016

Study contacts

Patricia Walker, MD, PhD
study director · Kythera Biopharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion